1002-047 CLEAR Wisdom
This is a long-term, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of bempedoic acid (ETC-1002) in patients with hyperlipidemia at high cardiovascular risk not adequately controlled by their lipid-modifying therapy.
The purpose of this study is to see if bempedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.